Combining trametinib and navitoclax to treat recurrent ovarian cancer
Official title: Evaluation of the Efficacy of Trametinib + Navitoclax in recurrent ovarian carcinoma
Funded at Dana-Farber Cancer Inst · NIH-10895326 · Data updated 2026-11-12
This study is testing a new combination treatment for women with recurrent ovarian cancer that hasn't responded to standard therapies, aiming to see if it can help improve their outcomes.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 3, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $390,649 |
| NIH project number | 5P50CA240243-05 |
| Project ID | NIH-10895326 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with recurrent ovarian cancer, particularly those with high grade serous carcinoma or other subtypes that exhibit resistance to platinum-based therapies.
✕Less likely to help
Patients with early-stage ovarian cancer or those who have not experienced treatment resistance may not benefit from this research.
What this research studies
This research investigates a new treatment approach for recurrent ovarian cancer, particularly focusing on high grade serous carcinoma, which often becomes resistant to standard therapies. The study aims to evaluate the effectiveness of a combination therapy that targets specific cancer pathways and proteins involved in cell survival. By using trametinib, which inhibits the MEK protein in the Ras-ERK pathway, alongside navitoclax, which targets anti-apoptotic proteins BCL2 and BCLXL, the research seeks to improve treatment outcomes for patients with resistant forms of ovarian cancer. Patients may be monitored for their response to this innovative therapy through clinical trials.
Why it matters
Potential benefit: If successful, this research could provide a new effective treatment option for patients with recurrent ovarian cancer who have limited responses to existing therapies.
How similar studies have gone: Previous studies have shown promising results with similar combination therapies targeting the Ras-ERK pathway and anti-apoptotic proteins, indicating potential for success in this approach.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Matulonis, Ursula Anne — Dana-Farber Cancer Inst
- Study coordinator: Matulonis, Ursula Anne
Related research
Other NIH-funded projects on the same topics.
-
Using imaging data to predict outcomes in ovarian cancer patients
This study is looking at how regular CT scans can be used to find important clues that help predict how well women with a specific type of ovarian cancer might do after treatment, so doctors can make better choices for their care.
-
Hippo/YAP pathway in aggressive ovarian cancer
Researchers aim to find out how a cell-control system called Hippo/YAP helps start and drive the most deadly form of ovarian cancer in women.
-
Blocking CDK7 as a new approach for aggressive ovarian cancer
This work explores whether blocking a protein called CDK7 can help treat women with high-grade serous ovarian cancer, especially tumors with CDK7 loss or BRCA-related DNA repair problems.
-
New methods to treat a specific type of ovarian cancer
This study is looking at a tough type of ovarian cancer called high-grade serous tubo-ovarian carcinoma to find out why it often doesn't respond to regular treatments, and it's testing new therapy combinations to help improve outcomes for patients like you.
-
A new CAR T cell therapy targeting ovarian cancer
This study is testing a new type of CAR T cell therapy for women with ovarian cancer that uses special immune cells to better target the cancer and includes a safety feature to help protect patients from side effects.
-
Targeting a specific protein to treat advanced ovarian cancer
This study is looking at a new way to help people with advanced ovarian cancer by targeting a specific protein that helps cancer cells survive, hoping to make current treatments work better for those who have few options left.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.